Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp T Meyer

Showing results (31-40 of 216) with videos related to

Pageof 22
Sort By:
Theranostics|January 9, 2026
Optimizing PSMA-617-based inhibitors through charged linker modifications: Insights into structure-activity relationshipsNicolas M Geis, Yvonne Braunwarth, Philipp T Meyer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2006
18F-CPFPX PET: on the generation of parametric images and the effect of scan durationPhilipp T Meyer, David Elmenhorst, Andreas Matusch, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2013
Amyloid-β load predicts medial temporal lobe dysfunction in Alzheimer dementiaLars Frings, Timo S Spehl, Wolfgang A Weber, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|April 11, 2025
Neuroimaging in multiple system atrophy: clinical implications and novel developmentsWolfgang H Jost, Alexander Rau, Joachim Brumberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 24, 2007
Test-retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PETDavid Elmenhorst, Philipp T Meyer, Andreas Matusch, et al.
Cancers|January 11, 2022
Early PSA Change after [<sup>177</sup>Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall SurvivalFelix Kind, Thomas F Fassbender, Geoffroy Andrieux, et al.
EJNMMI Research|April 11, 2022
Bone marrow impairment during early [<sup>177</sup>Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?Felix Kind, Kerstin Michalski, Elham Yousefzadeh-Nowshahr, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 17, 2018
Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic populationLars Frings, Sabine Hellwig, Tobias Bormann, et al.
Plos One|December 25, 2015
(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive TumorsEleni Gourni, Coline Canovas, Victor Goncalves, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2021
Assessing Response to [<sup>177</sup>Lu]PSMA Radioligand Therapy using modified PSMA PET Progression CriteriaKerstin Michalski, Claudius Klein, Tonio Brueggemann, et al.
Pageof 22

Showing results (31-40 of 216) with videos related to

Sort By:
Pageof 22
Theranostics|January 9, 2026
Optimizing PSMA-617-based inhibitors through charged linker modifications: Insights into structure-activity relationshipsNicolas M Geis, Yvonne Braunwarth, Philipp T Meyer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2006
18F-CPFPX PET: on the generation of parametric images and the effect of scan durationPhilipp T Meyer, David Elmenhorst, Andreas Matusch, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2013
Amyloid-β load predicts medial temporal lobe dysfunction in Alzheimer dementiaLars Frings, Timo S Spehl, Wolfgang A Weber, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|April 11, 2025
Neuroimaging in multiple system atrophy: clinical implications and novel developmentsWolfgang H Jost, Alexander Rau, Joachim Brumberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 24, 2007
Test-retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PETDavid Elmenhorst, Philipp T Meyer, Andreas Matusch, et al.
Cancers|January 11, 2022
Early PSA Change after [<sup>177</sup>Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall SurvivalFelix Kind, Thomas F Fassbender, Geoffroy Andrieux, et al.
EJNMMI Research|April 11, 2022
Bone marrow impairment during early [<sup>177</sup>Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?Felix Kind, Kerstin Michalski, Elham Yousefzadeh-Nowshahr, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 17, 2018
Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic populationLars Frings, Sabine Hellwig, Tobias Bormann, et al.
Plos One|December 25, 2015
(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive TumorsEleni Gourni, Coline Canovas, Victor Goncalves, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2021
Assessing Response to [<sup>177</sup>Lu]PSMA Radioligand Therapy using modified PSMA PET Progression CriteriaKerstin Michalski, Claudius Klein, Tonio Brueggemann, et al.
Pageof 22